Orphazyme prepares for USD 50m capital hunt after nightmare year
![Photo: Orphazyme/PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13433881.ece/ALTERNATES/schema-16_9/doc7i9iaa17gtl14iwg6hur.jpg)
Biotech business Orphazyme, which is based in Copenhagen, Denmark, is planning to raise USD 50m through an American Depositary Shares (ADSs) issuance, it reports in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Orphazyme fails trial in muscle wasting disease
For subscribers
Orphazyme cuts guidance following FDA setback
For subscribers